Tiomolibdic acid

Last updated

Tiomolibdic acid
Tiomolibdic acid.svg
Clinical data
Trade names Decuprate
Other namesTetrathiomolybdic acid; choline salt: ATN-224, WTX101, ALXN1840
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
Formula H2MoS4
Molar mass 226.21 g·mol−1
3D model (JSmol)
  • S=[Mo](=S)(S)S
  • InChI=1S/Mo.2H2S.2S/h;2*1H2;;/q+2;;;;/p-2
  • Key:IEGNLZVDENYZEJ-UHFFFAOYSA-L

Tiomolibdic acid (trade name Decuprate) is a chelating agent under investigation for the treatment of cancer and of Wilson's disease, [1] a rare and potentially fatal disease in which the body cannot regulate copper. It is developed by Wilson Therapeutics and used in form of the salt bis-choline tetrathiomolybdate.

Contents

Wilson's disease is an autosomal recessive genetic disorder that is manifested by serious hepatic, neurologic or psychiatric symptoms. The disease is fatal if left untreated. It is estimated that 1 individual in every 30,000 to 100,000 worldwide has Wilson's disease. [2]

Bis-choline tetrathiomolybdate has been evaluated in clinical trials in patients with various forms of cancer [3] [4] [5] and has received orphan designation in the US and EU as a potential therapy against Wilson's disease. [6] [7]

Pharmacology

Mechanism of action

Tiomolibdic acid selectively forms highly stable complexes with copper and proteins. These complexes are then believed to be primarily excreted via the bile, restoring the normal excretion route of copper that is impaired in patients with Wilson's disease. [8] [9] [10]

The binding and excretion mechanism is stable; whereas many de-coppering agents form unstable complexes that are excreted via urine. [11]

Bis-choline tetrathiomolybdate Bis-choline tetrathiomolybdate.svg
Bis-choline tetrathiomolybdate

Clinical trials

As of November 2014, a Phase 2, multi-centre, open-label study was recruiting newly diagnosed Wilson's disease patients 18 and older to evaluate the efficacy and safety of bis-choline tetrathiomolybdate administration over a 24-week period. [12] [13]

As of 2016, tetrathiomolybdate had been tested in over 500 patients for up to seven years, primarily in oncology [3] [4] [5] [14] [15] [16] [17] [18] [19] [20] and Wilson's disease, [21] [22] [23] [24] as well as some other clinical pathologies. [25] [26]

The data suggest that bis-choline tetrathiomolybdate can rapidly lower and control toxic free copper levels and improve clinical symptoms in Wilson's disease patients. The data also suggest that it is generally well tolerated, with the potential for a reduced risk of neurological worsening after initiation of therapy compared to existing therapies. [22] [23] [24]

Dosing

Previous clinical studies with bis-choline tetrathiomolybdate in oncology patients have shown that it can lower and maintain copper levels using a once or twice daily oral dosing. [4] [5] This may be helpful since untreated Wilson's disease may lead to death within several years of the onset of symptoms, [27] and medication use should continue throughout the patient's lifespan. Patient compliance is crucial for clinical improvement, and it is a particular challenge for Wilson's disease patients taking de-coppering treatments. [28]

Society and culture

Names

Tiomolibdic acid is the recommended International nonproprietary name (INN). [29]

Related Research Articles

<span class="mw-page-title-main">Wilson's disease</span> Genetic multisystem copper-transport disease

Wilson's disease is a genetic disorder characterized by the excess build-up of copper in the body. Symptoms are typically related to the brain and liver. Liver-related symptoms include vomiting, weakness, fluid build-up in the abdomen, swelling of the legs, yellowish skin, and itchiness. Brain-related symptoms include tremors, muscle stiffness, trouble in speaking, personality changes, anxiety, and psychosis.

<span class="mw-page-title-main">Cholangiocarcinoma</span> Cancer of the bile ducts

Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts. Symptoms of cholangiocarcinoma may include abdominal pain, yellowish skin, weight loss, generalized itching, and fever. Light colored stool or dark urine may also occur. Other biliary tract cancers include gallbladder cancer and cancer of the ampulla of Vater.

<span class="mw-page-title-main">Glioblastoma</span> Aggressive type of brain cancer

Glioblastoma, previously known as glioblastoma multiforme (GBM), is the most aggressive and most common type of cancer that originates in the brain, and has a very poor prognosis for survival. Initial signs and symptoms of glioblastoma are nonspecific. They may include headaches, personality changes, nausea, and symptoms similar to those of a stroke. Symptoms often worsen rapidly and may progress to unconsciousness.

<span class="mw-page-title-main">Proton therapy</span> Medical Procedure

In medicine, proton therapy, or proton radiotherapy, is a type of particle therapy that uses a beam of protons to irradiate diseased tissue, most often to treat cancer. The chief advantage of proton therapy over other types of external beam radiotherapy is that the dose of protons is deposited over a narrow range of depth; hence in minimal entry, exit, or scattered radiation dose to healthy nearby tissues.

<span class="mw-page-title-main">Cetuximab</span> Pharmaceutical drug

Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion.

<span class="mw-page-title-main">Neuroblastoma</span> Genetically inherited cancer of certain nerve tissues

Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently starts from one of the adrenal glands but can also develop in the head, neck, chest, abdomen, or spine. Symptoms may include bone pain, a lump in the abdomen, neck, or chest, or a painless bluish lump under the skin.

<span class="mw-page-title-main">Ammonium tetrathiomolybdate</span> Chemical compound

Ammonium tetrathiomolybdate is the chemical compound with the formula (NH4)2MoS4. This bright red ammonium salt is an important reagent in the chemistry of molybdenum and has been used as a building block in bioinorganic chemistry. The thiometallate (see metallate) anion has the distinctive property of undergoing oxidation at the sulfur centers concomitant with reduction of the metal from Mo(VI) to Mo(IV).

Matuzumab is a humanized monoclonal antibody for the treatment of cancer. It binds to the epidermal growth factor receptor (EGFR) with high affinity. The mouse monoclonal antibody (mAb425) from which matuzumab was developed at the Wistar Institute in Philadelphia, Pennsylvania

Mitumomab (BEC-2) is a mouse anti-BEC-2 monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system. It was developed by ImClone and Merck.

<span class="mw-page-title-main">Cediranib</span> Chemical compound

Cediranib is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.

A paraneoplastic syndrome is a syndrome that is the consequence of a tumor in the body. It is specifically due to the production of chemical signaling molecules by tumor cells or by an immune response against the tumor. Unlike a mass effect, it is not due to the local presence of cancer cells.

<span class="mw-page-title-main">HPV-positive oropharyngeal cancer</span> Cancer of the throat

Human papillomavirus-positive oropharyngeal cancer, is a cancer of the throat caused by the human papillomavirus type 16 virus (HPV16). In the past, cancer of the oropharynx (throat) was associated with the use of alcohol or tobacco or both, but the majority of cases are now associated with the HPV virus, acquired by having oral contact with the genitals of a person who has a genital HPV infection. Risk factors include having a large number of sexual partners, a history of oral-genital sex or anal–oral sex, having a female partner with a history of either an abnormal Pap smear or cervical dysplasia, having chronic periodontitis, and, among men, younger age at first intercourse and a history of genital warts. HPV-positive OPC is considered a separate disease from HPV-negative oropharyngeal cancer.

<span class="mw-page-title-main">Phosphoinositide 3-kinase inhibitor</span>

Phosphoinositide 3-kinase inhibitors are a class of medical drugs that are mainly used to treat advanced cancers. They function by inhibiting one or more of the phosphoinositide 3-kinase (PI3K) enzymes, which are part of the PI3K/AKT/mTOR pathway. This signal pathway regulates cellular functions such as growth and survival. It is strictly regulated in healthy cells, but is always active in many cancer cells, allowing the cancer cells to better survive and multiply. PI3K inhibitors block the PI3K/AKT/mTOR pathway and thus slow down cancer growth. They are examples of a targeted therapy. While PI3K inhibitors are an effective treatment, they can have very severe side effects and are therefore only used if other treatments have failed or are not suitable.

<span class="mw-page-title-main">Copper in biology</span>

Copper is an essential trace element that is vital to the health of all living things. In humans, copper is essential to the proper functioning of organs and metabolic processes. Also, in humans, copper helps maintain the nervous system, immune system, brain development, and activates genes, as well as assisting in the production of connective tissues, blood vessels, and energy. The human body has complex homeostatic mechanisms which attempt to ensure a constant supply of available copper, while eliminating excess copper whenever this occurs. However, like all essential elements and nutrients, too much or too little nutritional ingestion of copper can result in a corresponding condition of copper excess or deficiency in the body, each of which has its own unique set of adverse health effects.

<span class="mw-page-title-main">Nintedanib</span> Chemical compound

Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.

<span class="mw-page-title-main">Neutron capture therapy of cancer</span> Nonsurgical therapeutic modality for treating locally invasive malignant tumors

Neutron capture therapy (NCT) is a type of radiotherapy for treating locally invasive malignant tumors such as primary brain tumors, recurrent cancers of the head and neck region, and cutaneous and extracutaneous melanomas. It is a two-step process: first, the patient is injected with a tumor-localizing drug containing the stable isotope boron-10 (10B), which has a high propensity to capture low energy "thermal" neutrons. The neutron cross section of 10B is 1,000 times more than that of other elements, such as nitrogen, hydrogen, or oxygen, that occur in tissue. In the second step, the patient is radiated with epithermal neutrons, the sources of which in the past have been nuclear reactors and now are accelerators that produce higher energy epithermal neutrons. After losing energy as they penetrate tissue, the resultant low energy "thermal" neutrons are captured by the 10B atoms. The resulting decay reaction yields high-energy alpha particles that kill the cancer cells that have taken up enough 10B.

Resimmune or A-dmDT390-bisFv(UCHT1) is an experimental drug — an anti-T cell immunotoxin — that is being investigated for the treatment of T cell blood cancers such as cutaneous T cell lymphoma (CTCL). It was developed by Doctors Neville, Woo, and Liu while at the National Institutes of Health (NIH) and is under exclusive license to Angimmune, LLC. The therapy has potential applications for lymphomas and T cell driven autoimmune diseases, including multiple sclerosis, and graft-versus-host disease following stem cell or bone marrow transplant.

<span class="mw-page-title-main">Wilson Therapeutics</span> Swedish biopharmaceutical company

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for rare diseases. The company is listed in the Mid-Cap segment on Nasdaq Stockholm with the stock ticker WTX.

<span class="mw-page-title-main">Melphalan flufenamide</span> Alkylating type cancer drug

Melphalan flufenamide, sold under the brand names Pepaxto and Pepaxti, is an anticancer medication used to treat multiple myeloma.

<span class="mw-page-title-main">Molybdenum in biology</span> Use of molybdenum by organisms

Molybdenum is an essential element in most organisms. It is most notably present in nitrogenase which is an essential part of nitrogen fixation.

References

  1. ↑ "Tiomolibdic acid". National Center for Advancing Translational Sciences. Retrieved 30 December 2021.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  2. ↑ Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML (February 2007). "Wilson's disease". Lancet. 369 (9559): 397–408. doi:10.1016/S0140-6736(07)60196-2. PMID   17276780. S2CID   24663871.
  3. 1 2 Berenson JR, Boccia RV, Bashey A, Levine AM, Koc ON, Callahan JA, et al. (2006). "Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients with Advanced Hematologic Malignancies Presentation at the Amer Soc Hematol 2006 Annual Meeting". Blood. 108. Abstract 2593.
  4. 1 2 3 Lin J, Zahurak M, Beer TM, Ryan CJ, Wilding G, Mathew P, et al. (July 2013). "A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer". Urologic Oncology. 31 (5): 581–8. doi:10.1016/j.urolonc.2011.04.009. PMC   3227793 . PMID   21816640.
  5. 1 2 3 Lowndes SA, Adams A, Timms A, Fisher N, Smythe J, Watt SM, et al. (November 2008). "Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors". Clinical Cancer Research. 14 (22): 7526–34. doi: 10.1158/1078-0432.CCR-08-0315 . PMID   19010871.
  6. ↑ Public summary of opinion on orphan designation: Choline tetrathiomolybdate for the treatment of Wilson's disease, EMA/COMP/795268/2012, ATN-224, 18 February 2013.
  7. ↑ Orphan Drug Designations and Approvals: choline tetrathiomolybdate Archived 9 February 2015 at the Wayback Machine , U.S. Food and Drug Administration, 25 August 2011
  8. ↑ Komatsu Y, Sadakata I, Ogra Y, Suzuki KT (February 2000). "Excretion of copper complexed with thiomolybdate into the bile and blood in LEC rats". Chemico-Biological Interactions. 124 (3): 217–31. Bibcode:2000CBI...124..217K. doi:10.1016/s0009-2797(99)00159-3. PMID   10728780.
  9. ↑ McQuaid A, Mason J (February 1991). "A comparison of the effects of penicillamine, trientine, and trithiomolybdate on [35S]-labeled metallothionein in vitro; implications for Wilson's disease therapy". Journal of Inorganic Biochemistry. 41 (2): 87–92. doi:10.1016/0162-0134(91)80002-y. PMID   2033396.
  10. ↑ Ogra Y, Ohmichi M, Suzuki KT (October 1995). "Systemic dispositions of molybdenum and copper after tetrathiomolybdate injection in LEC rats". Journal of Trace Elements in Medicine and Biology. 9 (3): 165–9. Bibcode:1995JTEMB...9..165O. doi:10.1016/S0946-672X(11)80042-8. PMID   8605606.
  11. ↑ Říha M, Karlíčková J, Filipský T, Macáková K, Hrdina R, Mladěnka P (June 2013). "Novel method for rapid copper chelation assessment confirmed low affinity of D-penicillamine for copper in comparison with trientine and 8-hydroxyquinolines". Journal of Inorganic Biochemistry. 123: 80–7. doi:10.1016/j.jinorgbio.2013.02.011. PMID   23563391.
  12. ↑ Clinical trial number NCT02273596 for "Efficacy and Safety Study of WTX101 in Adult Wilson Disease Patients" at ClinicalTrials.gov
  13. ↑ "Wilson Disease Clinical Trials. Phase 2 Study in Newly Diagnosed Wilson Disease Patients with WTX101 (Tetrathiomolybdate)". Wilson Disease Association. 2009. Archived from the original on 9 February 2015.
  14. ↑ Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, et al. (January 2000). "Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study". Clinical Cancer Research. 6 (1): 1–10. PMID   10656425.
  15. ↑ Gartner EM, Griffith KA, Pan Q, Brewer GJ, Henja GF, Merajver SD, et al. (April 2009). "A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer". Investigational New Drugs. 27 (2): 159–65. doi:10.1007/s10637-008-9165-9. PMC   4171042 . PMID   18712502.
  16. ↑ Henry NL, Dunn R, Merjaver S, Pan Q, Pienta KJ, Brewer G, et al. (2006). "Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer". Oncology. 71 (3–4): 168–75. doi:10.1159/000106066. PMID   17641535. S2CID   25861052.
  17. ↑ Jain S, Cohen J, Ward MM, Kornhauser N, Chuang E, Cigler T, et al. (June 2013). "Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse". Annals of Oncology. 24 (6): 1491–8. doi:10.1093/annonc/mds654. PMC   3707432 . PMID   23406736.
  18. ↑ Pass HI, Brewer GJ, Dick R, Carbone M, Merajver S (August 2008). "A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results". The Annals of Thoracic Surgery. 86 (2): 383–9, discussion 390. doi: 10.1016/j.athoracsur.2008.03.016 . PMID   18640301.
  19. ↑ Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, et al. (May 2003). "Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer". Clinical Cancer Research. 9 (5): 1666–72. PMID   12738719.
  20. ↑ Schneider BJ, Lee JS, Hayman JA, Chang AC, Orringer MB, Pickens A, et al. (April 2013). "Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer". Investigational New Drugs. 31 (2): 435–42. doi:10.1007/s10637-012-9864-0. PMC   4418641 . PMID   22847786.
  21. ↑ Roberts EA, Schilsky ML (June 2008). "Diagnosis and treatment of Wilson disease: an update". Hepatology. 47 (6): 2089–111. doi: 10.1002/hep.22261 . PMID   18506894.
  22. 1 2 Brewer GJ, Askari F, Dick RB, Sitterly J, Fink JK, Carlson M, et al. (August 2009). "Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine". Translational Research. 154 (2): 70–7. doi:10.1016/j.trsl.2009.05.002. PMID   19595438.
  23. 1 2 Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, Kluin KJ, et al. (April 2006). "Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease". Archives of Neurology. 63 (4): 521–7. doi: 10.1001/archneur.63.4.521 . PMID   16606763.
  24. 1 2 Brewer GJ, Hedera P, Kluin KJ, Carlson M, Askari F, Dick RB, et al. (March 2003). "Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy". Archives of Neurology. 60 (3): 379–85. doi: 10.1001/archneur.60.3.379 . PMID   12633149.
  25. ↑ Askari F, Innis D, Dick RB, Hou G, Marrero J, Greenson J, et al. (March 2010). "Treatment of primary biliary cirrhosis with tetrathiomolybdate: results of a double-blind trial". Translational Research. 155 (3): 123–30. doi:10.1016/j.trsl.2009.09.009. PMID   20171597.
  26. ↑ Vine AK, Brewer GJ (2002). "Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration". Transactions of the American Ophthalmological Society. 100: 73–6, discussion 76-7. PMC   1358949 . PMID   12545680.
  27. ↑ Członkowska A, Tarnacka B, Litwin T, Gajda J, Rodo M (June 2005). "Wilson's disease-cause of mortality in 164 patients during 1992-2003 observation period". Journal of Neurology. 252 (6): 698–703. doi:10.1007/s00415-005-0720-4. PMID   15742108. S2CID   34212689.
  28. ↑ Masełbas W, Chabik G, Członkowska A (2010). "Persistence with treatment in patients with Wilson disease". Neurologia I Neurochirurgia Polska. 44 (3): 260–3. doi:10.1016/s0028-3843(14)60040-2. PMID   20625962.
  29. ↑ World Health Organization (2010). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 63". WHO Drug Information. 24 (1). hdl: 10665/74530 .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.